Cardinal Capital Management Inc. Trims Holdings in Pfizer Inc. (NYSE:PFE)

Cardinal Capital Management Inc. cut its holdings in Pfizer Inc. (NYSE:PFE – Get Rating) by 3.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,950 shares of the biopharmaceutical company’s stock after selling 600 shares during the quarter. Cardinal Capital Management Inc.’s holdings in Pfizer were worth $929,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Norges Bank purchased a new stake in Pfizer during the 4th quarter valued at about $3,351,891,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its position in Pfizer by 577.8% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 12,247,903 shares of the biopharmaceutical company’s stock valued at $715,270,000 after purchasing an additional 10,440,786 shares during the last quarter. Coatue Management LLC purchased a new stake in Pfizer during the 4th quarter valued at about $608,919,000. Darwin Global Management Ltd. purchased a new stake in Pfizer during the 4th quarter valued at about $454,553,000. Finally, State Street Corp grew its position in Pfizer by 1.8% during the 4th quarter. State Street Corp now owns 284,816,832 shares of the biopharmaceutical company’s stock valued at $16,818,434,000 after purchasing an additional 5,013,651 shares during the last quarter. 66.50% of the stock is currently owned by hedge funds and other institutional investors.

NYSE PFE opened at $49.07 on Thursday. Pfizer Inc. has a 12 month low of $38.82 and a 12 month high of $61.71. The stock has a market cap of $275.33 billion, a price-to-earnings ratio of 11.25, a PEG ratio of 0.56 and a beta of 0.76. The company’s 50 day moving average is $50.57 and its two-hundred day moving average is $52.22. The company has a current ratio of 1.39, a quick ratio of 1.13 and a debt-to-equity ratio of 0.43.

Pfizer (NYSE:PFE – Get Rating) last released its earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 EPS for the quarter, missing analysts’ consensus estimates of $1.66 by ($0.04). Pfizer had a return on equity of 38.29% and a net margin of 26.97%. The firm had revenue of $25.66 billion for the quarter, compared to the consensus estimate of $24.73 billion. During the same quarter in the previous year, the business posted $0.93 EPS. Pfizer’s revenue was up 76.8% on a year-over-year basis. Sell-side analysts forecast that Pfizer Inc. will post 6.61 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Friday, June 10th. Shareholders of record on Friday, May 13th were paid a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 3.26%. The ex-dividend date was Thursday, May 12th. Pfizer’s payout ratio is currently 36.70%.

In other Pfizer news, SVP Jennifer B. Damico sold 4,218 shares of the stock in a transaction on Tuesday, June 7th. The shares were sold at an average price of $53.96, for a total transaction of $227,603.28. Following the completion of the transaction, the senior vice president now owns 10,846 shares in the company, valued at $585,250.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP William R. Carapezzi, Jr. sold 32,908 shares of Pfizer stock in a transaction on Thursday, May 12th. The stock was sold at an average price of $50.00, for a total transaction of $1,645,400.00. Following the completion of the transaction, the executive vice president now directly owns 38,146 shares of the company’s stock, valued at $1,907,300. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 41,126 shares of company stock valued at $2,075,003. Company insiders own 0.05% of the company’s stock.

Several analysts recently commented on the stock. Citigroup increased their price objective on shares of Pfizer from $46.00 to $57.00 and gave the company a “neutral” rating in a research report on Tuesday, April 5th. Wells Fargo & Company lowered their target price on shares of Pfizer from $60.00 to $55.00 in a research note on Wednesday, May 4th. StockNews.com upgraded shares of Pfizer from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, April 19th. JPMorgan Chase & Co. set a $57.00 target price on shares of Pfizer in a research note on Tuesday, May 3rd. Finally, Barclays set a $52.00 target price on shares of Pfizer in a research note on Tuesday, May 17th. Nine investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $57.26.

Pfizer Company Profile (Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

See Also